Informations: All download services should be available again. In case you still experience any issues, please contact us.
Informations:
Erreur:
ID
15502
Description
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00151086
Lien
https://clinicaltrials.gov/show/NCT00151086
Mots-clés
Versions (1)
- 01/06/2016 01/06/2016 -
Téléchargé le
1 juin 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Prostate Cancer NCT00151086
Eligibility Prostate Cancer NCT00151086
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00151086
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
adenocarcinoma of the prostate
Item
patients must have a histologic diagnosis of adenocarcinoma of the prostate. (no evidence of brain metastasis or untreated spinal cord compression.)
boolean
C0600139 (UMLS CUI [1])
androgen suppression therapy
Item
patients on total androgen suppression therapy must undergo nonsteroidal antiandrogen withdrawal and demonstrate at rising psa (prostate specific antigen) 4 weeks after withdrawal for flutamide and 6 weeks after withdrawal for bicalutamide or nilutamide.
boolean
measurable soft tissue disease
Item
patients must have measurable soft tissue disease or evaluable (abnormal bone scan and/or elevated psa). if psa is the only evidence of progressive disease it must be greater than or equal to 4ng/ml.
boolean
C0263978 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
C1513041 (UMLS CUI [1,2])
bone marrow renal and liver function
Item
adequate bone marrow, renal and liver function
boolean
C0005953 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
ecog
Item
ecog (eastern cooperative oncology group) performance status of 0-2 (a measure of general well being on a scale of 0-5 where 0 represents asymptomatic and 5 represents death)
boolean
C1520224 (UMLS CUI [1])
age
Item
must be at least 18 years of age
boolean
C0001779 (UMLS CUI [1])
life expectancy
Item
must have a life expectancy of greater than or equal to 12 weeks
boolean
C0023671 (UMLS CUI [1])
vinca alkaloid-based cytotoxic chemotherapy
Item
have previously received vinca alkaloid-based cytotoxic chemotherapy or radiation to greater than or equal to 50% of the total bone marrow.
boolean
C0042672 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2])
C0392920 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2])
brain metastasis
Item
evidence of brain metastasis
boolean
C0220650 (UMLS CUI [1])
spinal cord compression
Item
spinal cord compression
boolean
C0037926 (UMLS CUI [1])
prior malignancy
Item
prior malignancy except for in situ carcinoma, nonmelanoma skin cancer, or adequately treated malignancy that has been inactive for less than 3 years
boolean
C0006826 (UMLS CUI [1])
preexisting neuropathy
Item
patients with preexisting neuropathy of greater than or equal to grade 2
boolean
C0442874 (UMLS CUI [1])
active gastrointestinal disease
Item
active gastrointestinal disease, or a disorder that alters gastrointestinal motility or absorption
boolean
C0017178 (UMLS CUI [1])